LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc. (“Northwest Biotherapeutics” or the “Company”) (NASDAQ:NWBO) concerning possible violations of federal securities laws. The investigation focuses on the Company’s operations and prospects.
Please contact us at (646) 539-8980, or at email@example.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Northwest Biotherapeutics is a biotechnology company engaged in the discovery and development of immunotherapy products to treat cancers in the United States and internationally. The Company is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The investigation is related to an article published by TheStreet.com on June 19, 2014, alleging that the MD Anderson Cancer Center “issued a stern rebuke to Northwest Biotherapeutics for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” The article further alleges that the vice president of clinical research at the MD Anderson Cancer Center stated that claims in certain of the Company’s press releases concerning the DCVax-Direct clinical trials are preliminary and unconfirmed. Following this news, the price of Northwest Biotherapeutics shares dropped nearly 20 percent in intraday trading on June 19, 2014.
If you purchased Northwest Biotherapeutics securities, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 122 East 42nd Street, Suite 2920, New York, NY 10168, at (646) 539-8980, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.